US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Decoy Therapeutics Inc

3.20

-0.0800-2.44%

Post-market: 3.200.00000.00%19:48 EDT

Volume:15.21K

Turnover:49.74K

Market Cap:2.10M

PE:-0.08

High:3.43

Open:3.30

Low:3.17

Close:3.28

52wk High:75.36

52wk Low:3.17

Shares:655.19K

Float Shares:652.09K

Volume Ratio:0.65

T/O Rate:2.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-40.3963

EPS(LYR):-129.1004

ROE:-827.77%

ROA:-73.35%

PB:0.49

PE(LYR):-0.02

Loading ...

Overview Company News Filings

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

THOMSON REUTERS

Decoy Therapeutics partners with hVIVO to advance D-MAV antivirals into Phase 1, Phase 2a studies

Decoy Therapeutics names MIT professor Brad Pentelute chair of scientific advisory board

Decoy Therapeutics Names Brad Pentelute, Mit Professor of Chemistry, as Chair of Scientific Advisory Board

THOMSON REUTERS

Press Release: Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board

Decoy Therapeutics announces 2026 annual shareholder meeting

Decoy Therapeutics Q1 net loss widens to $2.22 million

Decoy Therapeutics executives present at peptide therapeutics conferences in Boston

Decoy Therapeutics to present at virtual investor Closing Bell event

Decoy Therapeutics CEO to join Virtual Investor Closing Bell webcast on business outlook

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

THOMSON REUTERS

BRIEF-Decoy Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Decoy Therapeutics regains Nasdaq minimum bid price compliance, avoids delisting

Decoy Therapeutics FY25 net loss widens to $12.5 million; R&D expenses climb to $8.9 million

Decoy Therapeutics partners with Quantori to build Google Cloud-native AI peptide design platform

Decoy Therapeutics Enters Strategic Partnership With Quantori to Deploy Google Cloud-Native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

THOMSON REUTERS

Decoy Therapeutics Inc - Google Cloud Funding to Increase Decoy Peptide Design Bandwidth by 25-100X

THOMSON REUTERS

Decoy Therapeutics Inc trading halted, news pending

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Inc. held a virtual special stockholder meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/DCOY/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DCOY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","market":"US","secType":"STK","nameCN":"Decoy Therapeutics Inc","latestPrice":3.2,"timestamp":1787342400000,"preClose":3.28,"halted":0,"volume":15212,"hourTrading":{"tag":"盘后","latestPrice":3.2,"preClose":3.2,"latestTime":"19:48 EDT","volume":71,"amount":229.12,"timestamp":1787356101436,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02439024390243891,"floatShares":652085,"shares":655185,"eps":-40.396286,"marketStatus":"Market Closed","change":-0.08,"latestTime":"08-21 16:00:00 EDT","open":3.3,"high":3.43,"low":3.17,"amount":49739.184480799995,"amplitude":0.079268,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-40.396286,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1422507600000,"exchange":"NASDAQ","adjPreClose":3.28,"preHourTrading":{"tag":"盘前","latestPrice":3.39,"preClose":3.28,"latestTime":"09:29 EDT","volume":150,"amount":496.32000000000005,"timestamp":1787318996871,"change":0.11,"changeRate":0.033537,"amplitude":0.112805},"postHourTrading":{"tag":"盘后","latestPrice":3.2,"preClose":3.2,"latestTime":"19:48 EDT","volume":71,"amount":229.12,"timestamp":1787356101436,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6501764991800081},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","floatShares":652085,"roa":"-73.35%","roe":"-827.77%","lyrEps":-129.100415,"volumeRatio":0.6501764991800081,"shares":655185,"dividePrice":0,"high":3.43,"amplitude":0.079268,"preClose":3.28,"low":3.17,"week52Low":3.17,"pbRate":"0.49","psRate":"9.21","week52High":75.36,"institutionHeld":0,"latestPrice":3.2,"eps":-40.396286,"divideRate":0,"volume":15212,"delay":0,"ttmEps":-40.396286,"open":3.3,"prevYearClose":7.7856,"prevWeekClose":3.58,"prevMonthClose":4.11,"prevQuarterClose":7.19,"fiveDayClose":3.58,"twentyDayClose":5.04,"sixtyDayClose":8.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DCOY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"DCOY","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-4.46},{"market":"US","date":"2026-05-08","symbol":"DCOY","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"post","actualEps":-4.18},{"market":"US","date":"2026-03-31","symbol":"DCOY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2026-03-09","symbol":"DCOY","defaultRemindTime":1773063000000,"type":"split","dateTimestamp":1773028800000,"forFactor":12,"toFactor":1,"ratio":12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DCOY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DCOY\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DCOY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DCOY","date":"2026-08-21","current":-0.079215,"percent":0.967532,"low":-1.594527,"twenty":-0.881334,"median":-0.262442,"eighty":-0.225153,"high":-0.129591,"avg":-0.494184,"sd":0.347117,"marketCap":2149006},"quantilePoints":[{"date":"2026-01-09","current":-0.982229,"twenty":-1.053663,"median":-1.026876,"eighty":-1.000088,"marketCap":4915816},{"date":"2026-01-16","current":-1.227403,"twenty":-1.203881,"median":-1.071522,"eighty":-1.040856,"marketCap":6142855},{"date":"2026-01-23","current":-0.957354,"twenty":-1.160688,"median":-1.045754,"eighty":-0.982229,"marketCap":4791324},{"date":"2026-01-30","current":-1.05749,"twenty":-1.109791,"median":-1.050666,"eighty":-0.994985,"marketCap":5292482},{"date":"2026-02-06","current":-0.790885,"twenty":-1.101882,"median":-1.039631,"eighty":-0.91832,"marketCap":3958189},{"date":"2026-02-13","current":-0.956844,"twenty":-1.071522,"median":-0.994921,"eighty":-0.926101,"marketCap":4788771},{"date":"2026-02-20","current":-1.018456,"twenty":-1.060296,"median":-0.989117,"eighty":-0.939163,"marketCap":5097126},{"date":"2026-02-27","current":-0.871249,"twenty":-1.05596,"median":-0.982229,"eighty":-0.908242,"marketCap":4360392},{"date":"2026-03-06","current":-0.74305,"twenty":-1.047719,"median":-0.957099,"eighty":-0.869974,"marketCap":3718783},{"date":"2026-03-13","current":-0.796199,"twenty":-1.041162,"median":-0.954292,"eighty":-0.863596,"marketCap":3984784},{"date":"2026-03-20","current":-0.84935,"twenty":-1.039708,"median":-0.934265,"eighty":-0.844716,"marketCap":4250791},{"date":"2026-03-27","current":-0.746769,"twenty":-1.027385,"median":-0.915268,"eighty":-0.830428,"marketCap":3737398},{"date":"2026-04-02","current":-0.671826,"twenty":-1.020803,"median":-0.90314,"eighty":-0.800664,"marketCap":3362328},{"date":"2026-04-10","current":-0.254968,"twenty":-1.004373,"median":-0.87465,"eighty":-0.787058,"marketCap":3191808},{"date":"2026-04-17","current":-0.249443,"twenty":-0.994908,"median":-0.869974,"eighty":-0.73327,"marketCap":3122652},{"date":"2026-04-24","current":-0.230321,"twenty":-0.987969,"median":-0.855197,"eighty":-0.507377,"marketCap":2883266},{"date":"2026-05-01","current":-0.257092,"twenty":-0.982688,"median":-0.845098,"eighty":-0.256242,"marketCap":3218406},{"date":"2026-05-08","current":-0.243919,"twenty":-0.982229,"median":-0.84006,"eighty":-0.250421,"marketCap":3053496},{"date":"2026-05-15","current":-0.184485,"twenty":-0.974422,"median":-0.810018,"eighty":-0.248296,"marketCap":2404495},{"date":"2026-05-22","current":-0.262442,"twenty":-0.962099,"median":-0.79992,"eighty":-0.247659,"marketCap":3420554},{"date":"2026-05-29","current":-0.322848,"twenty":-0.95715,"median":-0.794073,"eighty":-0.248169,"marketCap":4207866},{"date":"2026-06-05","current":-0.27387,"twenty":-0.956742,"median":-0.781317,"eighty":-0.248169,"marketCap":3569505},{"date":"2026-06-12","current":-0.24081,"twenty":-0.95567,"median":-0.74491,"eighty":-0.247404,"marketCap":3138611},{"date":"2026-06-18","current":-0.24285,"twenty":-0.952787,"median":-0.706406,"eighty":-0.245537,"marketCap":3165209},{"date":"2026-06-26","current":-0.241544,"twenty":-0.945899,"median":-0.6697,"eighty":-0.244973,"marketCap":3148186},{"date":"2026-07-02","current":-0.311012,"twenty":-0.942429,"median":-0.364072,"eighty":-0.244891,"marketCap":4053596},{"date":"2026-07-10","current":-0.255707,"twenty":-0.926101,"median":-0.334889,"eighty":-0.244891,"marketCap":3332779},{"date":"2026-07-17","current":-0.244483,"twenty":-0.91832,"median":-0.322848,"eighty":-0.24285,"marketCap":3186488},{"date":"2026-07-24","current":-0.201627,"twenty":-0.915268,"median":-0.304685,"eighty":-0.239993,"marketCap":2627921},{"date":"2026-07-31","current":-0.159996,"twenty":-0.910668,"median":-0.29693,"eighty":-0.235273,"marketCap":2085314},{"date":"2026-08-07","current":-0.16571,"twenty":-0.904416,"median":-0.286523,"eighty":-0.233302,"marketCap":2159790},{"date":"2026-08-14","current":-0.129959,"twenty":-0.896201,"median":-0.26684,"eighty":-0.229711,"marketCap":1877847},{"date":"2026-08-21","current":-0.148725,"twenty":-0.881334,"median":-0.262442,"eighty":-0.225153,"marketCap":2149006}],"updateTime":1787508781563},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DCOY\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640901585","title":"Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901585","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901585?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488029,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA5Q3C6H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955206","title":"Decoy Therapeutics partners with hVIVO to advance D-MAV antivirals into Phase 1, Phase 2a studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955206","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640955206?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:06","pubTimestamp":1780311998,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics signed a strategic development initiative with clinical partner hVIVO to move its lead D-MAV antiviral into Phase 1 and Phase 2a studies.hVIVO will support trial planning, regulatory strategy, translational modeling, and preparation of European and UK clinical trial submissions, including EMA and MHRA interactions.The work is intended to create a reusable development template across Decoy’s D-MAV portfolio, subject to regulatory feedback.Decoy plans to pursue early proof-of-concept studies with hVIVO, while also targeting US registration with the FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief on June 01, 2026, and is solely r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL3qzrCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514437","title":"Decoy Therapeutics names MIT professor Brad Pentelute chair of scientific advisory board","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514437","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514437?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:15","pubTimestamp":1779797739,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics named Brad L. Pentelute as chair of its scientific advisory board on May 26, 2026.Pentelute is a co-founder of Decoy. He has served as a technology adviser since inception.He is a professor of chemistry at MIT. His work focuses on peptide synthesis, protein engineering, rapid flow synthesis.He succeeds Shahin Gharakhanian as SAB chair. Gharakhanian will continue working with the company.Pentelute will help guide the IMP3ACT platform, supporting development of designable multi-antivirals toward clinical-stage progress.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL3gvQgJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514924","title":"Decoy Therapeutics Names Brad Pentelute, Mit Professor of Chemistry, as Chair of Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514924?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:15","pubTimestamp":1779797700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA4TRHDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514148","title":"Press Release: Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514148","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514148?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:15","pubTimestamp":1779797700,"startTime":"0","endTime":"0","summary":"Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development. As Chair of the SAB, Dr. Pentelute will help guide the scientific direction of Decoy's IMP ACT platform and its expanding pipeline of Designable Multi-Antivirals , a new category of antivirals engineered to target shared viral mechanisms, enabling a single drug to work across multiple viral threats. IMP ACT, Decoy's proprietary peptide conjugate platform, integrates AI-enabled design with rapid synthesis to advance candidates faster than traditional approaches.Dr. Pentelute is a leader in the chemistry of peptides and proteins, with research that spans rapid flow peptide synthesis, intracellular delivery, and the discovery of selective binders for therapeutic targets. His laboratory at MIT has pioneered automated technologies that dramatically compress the time required to design, build, and test new peptide therapeutics, an approach central to the IMP ACT pl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK6515","BK4539","TM","BK4099","LENZ","BK4604","BK4007","BK4588","BK6062","M11.SI","03160","BK4585","BK4139","DCOY","MIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636861041","title":"Decoy Therapeutics announces 2026 annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2636861041","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636861041?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:09","pubTimestamp":1779221373,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics will hold its 2026 annual meeting of stockholders in Houston on July 14, 2026.Stockholders on record as of May 22, 2026 will be eligible to vote at the meeting.The company set May 29, 2026 as the deadline for shareholder proposals intended for inclusion in the proxy materials.May 29, 2026 is also the cutoff for advance notices to nominate director candidates or submit other business for consideration at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsib","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL8VhtJy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634462202","title":"Decoy Therapeutics Q1 net loss widens to $2.22 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634462202","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634462202?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:46","pubTimestamp":1778273200,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics posted a net loss of USD 2.22 million, widening from USD 1.71 million a year earlier.Research and development expenses more than doubled to 749,813, driven mainly by the November 2025 merger and addition of the IMP3ACT  program.General and administrative costs edged down to USD 1.53 million from USD 1.64 million, while interest income and other rose to 59,111 from 9,162.Cash, cash equivalents and restricted cash totaled USD 7.8 million, including about USD 3 million restricted under the Gates Foundation grant, with funding expected to last into late 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Dat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL7wLWQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630391920","title":"Decoy Therapeutics executives present at peptide therapeutics conferences in Boston","url":"https://stock-news.laohu8.com/highlight/detail?id=2630391920","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630391920?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:45","pubTimestamp":1777293948,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics executives will present at two peptide therapeutics conferences in Boston during week of April 27, 2026.April 28: CSO Barbara Hibner, CTO Michael Lipp will present a case study on peptide conjugate antiviral therapeutics at 3rd Annual Peptide-Based Therapeutics Summit.April 29: Technology advisor Bradley Pentelute will deliver opening Day 1 presentation at Peptide-Based Therapeutics Summit.April 30: CBO Peter Marschel will lead a 60-minute roundtable on computational peptide design at Oligonucleotide & Peptides HubXchange.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL3QsvPV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626718260","title":"Decoy Therapeutics to present at virtual investor Closing Bell event","url":"https://stock-news.laohu8.com/highlight/detail?id=2626718260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626718260?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:36","pubTimestamp":1775738179,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics to participate in Virtual Investor Closing Bell webcast on April 9, 2026 at 4:00 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLdbqrz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625745206","title":"Decoy Therapeutics CEO to join Virtual Investor Closing Bell webcast on business outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2625745206","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625745206?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:15","pubTimestamp":1775481347,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics CEO Rick Pierce will join a Virtual Investor Closing Bell event on April 9, 2026 at 4:00 PM ET.Session will provide corporate overview and 2026 business outlook.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDLcNGrW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625674522","title":"Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625674522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625674522?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:15","pubTimestamp":1775481300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nTUA9LC1NR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624250474","title":"BRIEF-Decoy Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624250474","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624250474?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:41","pubTimestamp":1775137292,"startTime":"0","endTime":"0","summary":"BRIEF-Decoy Therapeutics Regains Compliance With Nasdaq Minimum Bid Price RequirementApril 2 (Reuters) - Decoy Therapeutics Inc DCOY.O:DECOY THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA1FTRR5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624501289","title":"Decoy Therapeutics regains Nasdaq minimum bid price compliance, avoids delisting","url":"https://stock-news.laohu8.com/highlight/detail?id=2624501289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624501289?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:04","pubTimestamp":1775135059,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics regained compliance with Nasdaq Capital Market minimum bid price rule on March 31, 2026.Any renewed breach of minimum bid price requirement during monitoring period would trigger a Nasdaq delisting determination letter.Decoy would be able to request a hearing with Nasdaq Hearings Panel if delisting process is initiated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL5rqVGx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624555334","title":"Decoy Therapeutics FY25 net loss widens to $12.5 million; R&D expenses climb to $8.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555334","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555334?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:06","pubTimestamp":1774991209,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics posted a net loss of USD 13 million for fiscal 2025.Research and development expense climbed to USD 8.9 million, driven by USD 8.5 million of acquired in-process R&D tied to the merger.General and administrative costs fell to USD 3.7 million.Cash and cash equivalents totaled USD 11 million at Dec. 31, including about USD 3 million restricted under the Gates Grant Agreement.Decoy expects its cash on hand to fund operations into late 2026, while warning it will need substantial additional capital to continue funding operations beyond 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analy","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL2Khn7W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618942099","title":"Decoy Therapeutics partners with Quantori to build Google Cloud-native AI peptide design platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2618942099","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618942099?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:32","pubTimestamp":1773232320,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics said it is collaborating with Quantori, with funding support from Google Cloud, to build a Google Cloud-native peptide design and molecular simulation platform. The platform is intended to integrate protein folding models, molecular dynamics simulations, and performance optimization tools into Decoy’s IMPACT design engine. Decoy expects the collaboration to increase its computational throughput by about 25x to 100x. Quantori will deploy a containerized, GPU-accelerated architecture using components of its Q-Suite platform.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL5WnV1N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618766942","title":"Decoy Therapeutics Enters Strategic Partnership With Quantori to Deploy Google Cloud-Native Integrated AI-Driven Peptide Design and Molecular Simulation Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2618766942","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618766942?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:30","pubTimestamp":1773232202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA7SPR2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618427369","title":"Decoy Therapeutics Inc - Google Cloud Funding to Increase Decoy Peptide Design Bandwidth by 25-100X","url":"https://stock-news.laohu8.com/highlight/detail?id=2618427369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618427369?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:30","pubTimestamp":1773232202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA7SPR2R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617593426","title":"Decoy Therapeutics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2617593426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617593426?lang=en_us&edition=fundamental","pubTime":"2026-03-07 08:50","pubTimestamp":1772844647,"startTime":"0","endTime":"0","summary":"19:50 EST Decoy Therapeutics (DCOY) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/decoy-therapeutics-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/decoy-therapeutics-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617540141","title":"Decoy Therapeutics Announces 1-for-12 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2617540141","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617540141?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:30","pubTimestamp":1772717448,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics Inc. announced a 1-for-12 reverse stock split that will take effect at 5:00 p.m. Eastern Time on March 6, 2026. The company’s shares are expected to begin trading on a split-adjusted basis on Nasdaq on March 9, 2026, under a new CUSIP number 79400X602. The move is intended to help Decoy regain compliance with Nasdaq’s $1.00 minimum bid price requirement and will reduce shares outstanding from about 6.38 million to roughly 532,000, with options and warrants adjusted accordingly.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL3cZzF6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614038099","title":"Decoy Therapeutics Inc. held a virtual special stockholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2614038099","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614038099?lang=en_us&edition=fundamental","pubTime":"2026-02-25 22:16","pubTimestamp":1772028981,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics Inc. held a virtual special meeting of stockholders on February 24, 2026. Stockholders approved the 2026 Equity Incentive Plan, approved an amendment to the certificate of incorporation to allow a reverse stock split at a ratio to be set by the board within a specified range, and approved authorization for one or more adjournments of the meeting to solicit additional proxies if needed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 25, 2026, and is solely responsible for the information con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL3dmQRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}]}}